Nuvig Therapeutics is a biotechnology company developing therapies to induce natural mechanisms to restore immune homeostasis.
Nuvig Therapeutics has raised $161.0M in total funding. The most recent round was Series B. The last funding was announced in December 2024.
Nuvig Therapeutics's investors include Norwest Venture Partners, B Capital, Novo Holdings, Mission BioCapital, Bristol-Myers Squibb.
Nuvig Therapeutics is headquartered in Redwood City, United States.
Nuvig Therapeutics is a biotechnology company developing therapies to induce natural mechanisms to restore immune homeostasis.
Nuvig Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nuvig Therapeutics — Funding & Investors." VCBacked, December 5, 2024, https://www.vcbacked.co/company/nuvig-therapeutics. Accessed July 20, 2026.
VCBacked. (2024). Nuvig Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/nuvig-therapeutics
{{cite web |title=Nuvig Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nuvig-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated